drugset / Trial / NCT02418767

Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

NCT02418767

Phase 1 Completed 42 enrolled OPKO Health, Inc. WCCT Global · collab
RandomizedParallel-groupQuadruple-blindOther

Summary

The study is a Phase 1, randomized, double-blind, vehicle-controlled, single-dose, three dose levels study in healthy Caucasian and Japanese male volunteers. Following a 4-week screening period, eligible male subjects will be stratified by ethnic group and will be randomized to one of six groups. On dosing day, designated as Day 1, each subject will receive single SC injection of study medication according to group allocation and will be followed up for a month for safety monitoring.

Timeline

Start
2015-01
Primary completion
2015-03
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatrogon Protein / enzyme biologic Subcutaneous

Indications